TheraRadar
← Back
Data updated: Jun 28, 2026

WOCKHARDT BIO AG

Generics

WOCKHARDT BIO AG is a generic drug manufacturer focused on Infectious Disease, Metabolic, Oncology. Key products include ZAYNICH.

1984
Since
24
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
1 Small Molecules

WOCKHARDT BIO AG at a Glance

  • Fast trial execution (5 months median completion)

WOCKHARDT BIO AG's Key Drugs

WOCKHARDT BIO AG's core commercial portfolio centers on ZAYNICH, spanning Infectious Disease and Metabolic — its most strategically important drugs approved in the last 15 years.

WOCKHARDT BIO AG's Recent FDA Approvals

WOCKHARDT BIO AG secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

ZAYNICH NDA
2026-05-29
cefepime hydrochloride
1 INDICATIONS AND USAGE ZAYNICH is a combination of cefepime, a cephalosporin antibacterial, and zidebactam, a beta-lactamase inhibitor and non-beta-lactam antibacterial indicated for the treatment of adult patients with complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible microorganisms. ( 1.1 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZAYNICH and other antibacterial drugs, ZAYNICH should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) 1.1 Complicated Urinary Tract Infections, including Pyelonephritis ZAYNICH is indicated for the treatment of adult patients with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae complex, and Pseudomonas aeruginosa . 1.2 Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZAYNICH and other antibacterial drugs, ZAYNICH should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

WOCKHARDT BIO AG's Therapeutic Areas

WOCKHARDT BIO AG's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Metabolic, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 29%
1 drugs Phase 3: 2 Phase 2: 1 Phase 1: 2
Metabolic 23%
0 drugs Phase 3: 2 Phase 1: 6
Oncology 19%
2 drugs
Neurology 19%
2 drugs
Cardiovascular 10%
1 drugs

WOCKHARDT BIO AG Pipeline Snapshot

WOCKHARDT BIO AG has 13 active clinical programs from ClinicalTrials.gov — 4 Phase 3, 1 Phase 2 and 8 Phase 1.

4
Phase 3
1
Phase 2
8
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • ZAYNICH leads revenue
  • Drug-level revenue analysis

Trial Catalysts

  • Infectious Disease pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison

Execution Intelligence

  • Phase 3: 2/4 completed
  • Speed: 5 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges